Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [194]
In the citing paper
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [88]
Citations
Cites
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003) · Nature Neuroscience · doi:10.1038/nn983 · Cited by 799
Self-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
“However, viral evolution techniques may enable the generation of AAV9 variants that target adult neurons by vascular deliver”
BackgroundSelf-citationViral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons
Tervo, D. G. R., Hwang, B.-Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K. D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.021 · Cited by 1,179
“Library Generation and Viral Production Four previously generated virus libraries were used at the start of the directed evolution procedure: (1) a random mutagenesis library, generated by subjecting the AAV2 cap gene (encoding virus proteins VP1-3 and assemblyactivating protein, AAP) to error-prone PCR (Maheshri et a…”
MethodInfluentialSelf-citationEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“99%, but studies with naturally occurring serotypes 56 and purpose-engineered capsids 57-59 have shown that even small differences in capsid sequence may affect tissue tropism of a vector and can be exploited to improve therapeutic outcomes.”
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
“have extended the error-prone PCR and DNA-shuffling strategy into the realm of AAV vectors by using a single AAV2 capsid gene and random mutations as a source of diversity to select for variants that can escape neutralizing antibodies [121,122].”
BackgroundAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“82 In addition, a DNA shuf fl ing-based approach has been utilized to generate diverse and extensive libraries of random chimeras by combining capsids from various parent AAV serotypes.”
MethodLong-range and local circuits for top-down modulation of visual cortex processing
Zhang, S., Xu, M., Kamigaki, T., Hoang Do, J. P., Chang, W.-C., Jenvay, S., Miyamichi, K., Luo, L., & Dan, Y. (2014) · Science · doi:10.1126/science.1254126 · Cited by 804
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Self-citationDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
“As we have previously reported (48, 49), random mutagenesis libraries were generated by subjecting the resulting AAV2 Y444F cap to errorprone PCR, as described.”
MethodSelf-citationDirected Evolution: Methodologies and Applications
Wang, Y., Xue, P., Cao, M., Yu, T., Lane, S. T., & Zhao, H. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00260 · Cited by 719
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
“Advances in vector design, such as AAV capsid modification, mutagenesis or gene shuffling, may expand the opportunity to target neurons in the adul”
BackgroundSelf-citationRetractedEngineering targeted viral vectors for gene therapy
Waehler, R., Russell, S. J., & Curiel, D. T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2141 · Cited by 687
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
“and by constructing large libraries of randomly shuffled capsid DNA that are placed under selective pressure for certain desired propertie”
BackgroundActivation of specific interneurons improves V1 feature selectivity and visual perception
Lee, S.-H., Kwan, A. C., Zhang, S., Phoumthipphavong, V., Flannery, J. G., Masmanidis, S. C., Taniguchi, H., Huang, Z. J., Zhang, F., Boyden, E. S., et al. (2012) · Nature · doi:10.1038/nature11312 · Cited by 593
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Polymers for gene delivery across length scales
Putnam, D. (2006) · Nature Materials · doi:10.1038/nmat1645 · Cited by 572
“Unlike PEGylation, where a synthetic polymer is used to hide immunogenic proteins on a virus, some investigators have explored the use of DNA shuffling technology to engineer immunogenicity out of viral vectors while maintaining their ability to deliver DNA to cell”
BackgroundTherapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
“Both mRNA and protein trans-splicing strategies have been used to reconstitute full-length gene editing agents that are split into two AAVs.”
BackgroundInfluentialGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Self-citationSelection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Self-citationAkache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
“Of particular benefit is the feasibility to pseudotype recombinant AAV genomes (typically derived from the AAV serotype 2 [AAV2] prototype) with capsids from any of the over 100 identified naturally occurring human or nonhuman viral isolates (4, 8, 9, 11, 25) or with synthetic “designer” shells engineered via capsid D…”
BackgroundPhase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“95,121,122 To improve the liver transduction of AAV5 while retaining its low seroprevalence, a library of AAV5 mutants was constructed via random mutagenesis and screened in Huh7 cells.”
BackgroundPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
“Preferably, in order to increase further the complexity, the plasmid library is further diversified by either errorprone PCR or staggered extension PCR (Maheshri et al., 2006).”
InfluentialThe once and future gene therapy
Bulaklak, K., & Gersbach, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19505-2 · Cited by 321
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
“Forward genetic studies have resulted in important findings (Adachi et al., 2014; Asuri et al., 2012; Bartel et al., 2012; Dalkara et al., 2013; Huttner et al., 2003; Koerber et al., 2008; Li et al., 2008; Lisowski et al., 2014; Maheshri et al., 2006; Mays et al., 2013; Perabo et al., 2003; Shen et al., 2007; Wu et al…”
BackgroundNathanson, J. L., Yanagawa, Y., Obata, K., & Callaway, E. M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.03.032 · Cited by 304
“…tropism (Bowles et al., 2003, Muller et al., 2003, Perabo et al., 2003, Rabinowitz et al., 2004, Warrington et al., 2004, Choi et al., 2005, Maheshri et al., 2006, Perabo et al., 2006, Wu et al., 2006a, Li et al., 2008, Van Vliet et al., 2008), or insertion of gene regulatory elements into…”
Virus-based nanoparticles (VNPs): Platform technologies for diagnostic imaging☆
MANCHESTER, M., & SINGH, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.014 · Cited by 292
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Self-citationGene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“8, which all showed more efficient gene transduction than wild-type capsid, while retaining tissue tropism in the presence of anti-AAV serum in vitro (74, 75).”
BackgroundNovel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Ellis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-74 · Cited by 252
“Expansion in the number of AAV serotypes, both through the identification of novel natural serotypes and new, engineered serotypes [16,23,25-35], has resulted in improved gene transfer to specific cell types in vivo.”
BackgroundLi, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
Matrices and scaffolds for DNA delivery in tissue engineering
De Laporte, L., & Shea, L. D. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.017 · Cited by 258
“Novel vectors are being identified using a range of strategies, such as rational design [24], directed evolution [25–27], and high throughput screening [28,29].”
BackgroundProgress in gene therapy for neurological disorders
Simonato, M., Bennett, J., Boulis, N. M., Castro, M. G., Fink, D. J., Goins, W. F., Gray, S. J., Lowenstein, P. R., Vandenberghe, L. H., Wilson, T. J., et al. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.56 · Cited by 252
Körbelin, J., Dogbevia, G., Michelfelder, S., Ridder, D. A., Hunger, A., Wenzel, J., Seismann, H., Lampe, M., Bannach, J., Pasparakis, M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506078 · Cited by 252
“…or other ligands (White et al, 2004, 2008; Work et al, 2004, 2006; Chen et al, 2009; Munch et al, 2013) or by capsid shuffling (Bowles et al, 2003; Maheshri et al, 2006; Grimm et al, 2008; Koerber et al, 2008; Gray et al, 2010; Lisowski et al, 2014) to abrogate their natural tropism 1 Hubertus…”
BackgroundInfluentialBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
Humoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243
“Clin Vaccine Immunol (2011) 18(9):1586–8.”
BackgroundOrganization of long-range inputs and outputs of frontal cortex for top-down control
Zhang, S., Xu, M., Chang, W.-C., Ma, C., Hoang Do, J. P., Jeong, D., Lei, T., Fan, J. L., & Dan, Y. (2016) · Nature Neuroscience · doi:10.1038/nn.4417 · Cited by 242
Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237
“shuffling, an approach independent of rational design (11).”
BackgroundImmune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Adeno-associated virus (AAV) vectors in cancer gene therapy
Santiago-Ortiz, J. L., & Schaffer, D. V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.001 · Cited by 228
Self-citationOvercoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Recombination in Eukaryotic Single Stranded DNA Viruses
Martin, D. P., Biagini, P., Lefeuvre, P., Golden, M., Roumagnac, P., & Varsani, A. (2011) · Viruses · doi:10.3390/v3091699 · Cited by 225
“Laboratory constructed geminivirus and parvovirus recombinants have revealed that recombination can potentially alter transmission vector specificities [219, 220] , degrees of pathogenicity [192, 221, 222] , host ranges [216, 223] , degrees of neutralizing antibody resistance [224] [225] [226] and tissue tropisms [221…”
BackgroundKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210
“The resulting viral fractions were desalted and concentrated with Amicon Ultra-15 Centrifugal Filter Units to a final volume of 200 ml. Vector was then titered for DNase-resistant vector genomes by real time PCR relative to a standard.”
MethodSelf-citationA myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection
Yang, L., Jiang, J., Drouin, L. M., Agbandje-Mckenna, M., Chen, C., Qiao, C., Pu, D., Hu, X., Wang, D.-Z., Li, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813207106 · Cited by 210
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types
Ravindra Kumar, S., Miles, T. F., Chen, X., Brown, D., Dobreva, T., Huang, Q., Ding, X., Luo, Y., Einarsson, P. H., Greenbaum, A., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0799-7 · Cited by 192
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 189
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
“Two such studies have been described to date [139,140].”
BackgroundAdeno-Associated Virus (AAV) Vectors in the CNS
McCown, T. (2005) · Current Gene Therapy · doi:10.2174/1566523054064995 · Cited by 184
“Thus, by using either error prone PCR amplification of the capsid DNA [33] or DNA shuffling of the capsid DNA [39], it is possible to create a library containing a large number of mutant capsid sequences.”
BackgroundMethodGray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185
Cronin, T., Vandenberghe, L. H., Hantz, P., Juttner, J., Reimann, A., Kacsó, Á., Huckfeldt, R. M., Busskamp, V., Kohler, H., Lagali, P. S., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404077 · Cited by 184
“…of multiple different rep/cap genes into each cell (which would lead to encapsidation of a non-“self-coding” genome), a low plasmid concentration was used for the triple transfection (Maheshri et al , 2006) — 150 ng of rep/cap library plasmid was used per 150-mm confluent HEK293 cell culture plate.”
Molecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181
Self-citationDNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny
Koerber, J. T., Jang, J.-H., & Schaffer, D. V. (2008) · Molecular Therapy · doi:10.1038/mt.2008.167 · Cited by 181
Self-citationDirected evolution of adeno-associated virus to an infectious respiratory virus
Excoffon, K. J. D. A., Koerber, J. T., Dickey, D. D., Murtha, M., Keshavjee, S., Kaspar, B. K., Zabner, J., & Schaffer, D. V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813365106 · Cited by 181
Self-citationImmunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Kotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169
Self-citationRNA editing: Expanding the potential of RNA therapeutics
Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.005 · Cited by 171
Viral Strategies for Targeting the Central and Peripheral Nervous Systems
Bedbrook, C. N., Deverman, B. E., & Gradinaru, V. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-062048 · Cited by 168
Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy
Chen, Y. H., Chang, M., & Davidson, B. L. (2009) · Nature Medicine · doi:10.1038/nm.2025 · Cited by 168
“Finally, the use of AAV libraries generated by inserting amino acid sequences into the viral capsid or by capsid shufflin”
MethodRapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning
Nonnenmacher, M., Wang, W., Child, M. A., Ren, X.-Q., Huang, C., Ren, A. Z., Tocci, J., Chen, Q., Bittner, K., Tyson, K., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.006 · Cited by 168
“Early designs of AAV-directed evolution were strictly tailored for in vitro selection in cultured cells and used helper adenovirus coinfection to enrich transduction-competent variants.(11,12,17,18) Helper-dependent selection is not easily accomplished in vivo, and library selection in the mouse initially relied on in…”
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Kwon, I., & Schaffer, D. V. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9431-0 · Cited by 164
“evolution (116) or single round library selection (151).”
Self-citationTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Directed evolution of novel adeno-associated viruses for therapeutic gene delivery
Bartel, M. A., Weinstein, J. R., & Schaffer, D. V. (2012) · Gene Therapy · doi:10.1038/gt.2012.20 · Cited by 162
Self-citationAdeno-associated virus serotypes for gene therapeutics
Lisowski, L., Tay, S. S., & Alexander, I. E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.07.006 · Cited by 159
Molecular Engineering of Viral Gene Delivery Vehicles
Schaffer, D. V., Koerber, J. T., & Lim, K.-I. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.10.061807.160514 · Cited by 159
Self-citationImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“A recent abstract showed coadministration of ImmTOR with belimumab reduced anti-AAV IgM antibodies, provided more durable suppression of anti-AAV IgG antibodies, and allowed for multiple re-administrations of an AAV8 vector in mice.”
BackgroundInfluentialGyörgy, B., Fitzpatrick, Z., Crommentuijn, M. H. W., Mu, D., & Maguire, C. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.032 · Cited by 153
“Other methods to overcome antibody neutralization include pre-treating naïve animals with anti-CD4 antibodies before vector administration (33), empty capsid decoys which absorb neutralizing antibodies (34), plasmapheresis to remove antibodies from blood (35), balloon catheters and saline flush (36), and engineered ca…”
BackgroundAdachi, K., Enoki, T., Kawano, Y., Veraz, M., & Nakai, H. (2014) · Nature Communications · doi:10.1038/ncomms4075 · Cited by 154
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“In addition to peptide insertion, the development of capsid shuffling [93] and directed evolution [94], discussed in Chapter 11, has generated many promising novel AAV variants.”
BackgroundAdeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
“…for rational or random amino acid (AA) substitution and insertion have been identified (Adachi et al. 2014, Boucas et al. 2009, Girod et al. 1999, Maheshri et al. 2006, Ogden et al.2019,Perabo et al.2006,Rabinowitz et al.1999,Vandenberghe et al.2009),and meth-ods for serotype-shuffled chimeric…”
BackgroundImmunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 163
Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H. A., Kleinschmidt, J. A., & Müller, O. J. (2011) · Gene Therapy · doi:10.1038/gt.2011.143 · Cited by 147
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. J., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 154
Park, H., Popescu, A., & Poo, M.-M. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.045 · Cited by 142
“AAV-hSyn-BDNF-pHluorin was packaged (serotype 2) and purified as reported previously (Maheshri et al., 2006).”
A Hypothalamic Switch for REM and Non-REM Sleep
Chen, K.-S., Xu, M., Zhang, Z., Chang, W.-C., Gaj, T., Schaffer, D. V., & Dan, Y. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.005 · Cited by 155
“…AAV2-CAG-DIO-TVA-mCherry (1012 to 1013 vector genomes per milliliter; AAV preparation followed previously reported protocol (Maheshri et al., 2006; Zhang et al., 2016)) and RV-DGeGFP+EnvA (108 to 109 vector genomes per milliliter; preparation followed previously reported…”
Self-citationDavidsson, M., Wang, G., Aldrin-Kirk, P., Cardoso, T., Nolbrant, S., Hartnor, M., Mudannayake, J., Parmar, M., & Björklund, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910061116 · Cited by 142
Adeno-Associated Virus Vectors as Therapeutic and Investigational Tools in the Cardiovascular System
Zacchigna, S., Zentilin, L., & Giacca, M. (2014) · Circulation Research · doi:10.1161/circresaha.114.302331 · Cited by 155
“4, contain mutations at critical antigenic sites and are thereby capable of evading neutralizing antibodies in human serum.(165) Notably, AAV capsid modification not only modifies receptor interaction and virus adsorption but also influences other steps in the viral life cycle, including endosomal release, trafficking…”
BackgroundViruses as Building Blocks for Materials and Devices
Fischlechner, M., & Donath, E. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603445 · Cited by 145
Adeno-Associated Virus Vectors and Neurological Gene Therapy
Ojala, D. S., Amara, D. P., & Schaffer, D. V. (2014) · The Neuroscientist · doi:10.1177/1073858414521870 · Cited by 158
Self-citationAdeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149
Tseng, Y.-S., & Agbandje‐McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 153
Adeno-Associated Virus Biology
Weitzman, M. D., & Linden, R. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_1 · Cited by 132
Virus engineering: functionalization and stabilization
Mateu, M. G. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq069 · Cited by 145
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
“Point mutations that resulted in the greatest resistance to human sera, screened for AAV neutralization ability, were R459K and N551D, resulting in 10-fold greater resistance [53], and E12A, K258N, T567S, N587I, and T716A, resulting in 100-fold greater resistance [52].”
BackgroundMethodAdeno-associated virus: fit to serve
Zinn, E. M., & Vandenberghe, L. H. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.07.008 · Cited by 134
Viral Vectors and Delivery Strategies for CNS Gene Therapy
Gray, S. J., Woodard, K., & Samulski, R. J. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.50 · Cited by 135
Asuri, P., Bartel, M. A., Vazin, T., Jang, J.-H., Wong, T. B., & Schaffer, D. V. (2012) · Molecular Therapy · doi:10.1038/mt.2011.255 · Cited by 119
Self-citationEngineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 127
Metadata
- Authors
- Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Schaffer, David V
- Venue
- Nature Biotechnology
- Published
- 2006-01-22
- Volume
- 24
- Issue
- 2
- Pages
- 198-204
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2102111681
- Cited by
- 538
- References
- 53
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 29 · 2023: 31 · 2022: 31 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 19 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 32 · 2013: 31 · 2012: 23
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- ALS Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV2, directed evolution, viral capsid, gene delivery vectors, heparin binding, antibody neutralization, high-throughput selection
- MeSH terms
- Adenoviridae, Genetic Vectors, Transfection, Genetic Therapy, Drug Delivery Systems, Gene Targeting, Directed Molecular Evolution, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.